Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
In patients with early-stage TNBC, a tissue-free, epigenomic assay demonstrated high specificity and sensitivity for metastatic recurrence. ctDNA detection in the neoadjuvant setting indicated poor prognosis, highlighting its potential role across breast cancer care.
Authors
- Ron Bose (ORCID: https://orcid.org/0000-0003-1977-8894)
- Rama Suresh (ORCID: https://orcid.org/0000-0003-1637-9994)
- Mingyang Cai (ORCID: https://orcid.org/0000-0001-8063-1002)
- Andrew A. Davis (ORCID: https://orcid.org/0000-0003-3663-2133)
- Cynthia X. Ma (ORCID: https://orcid.org/0000-0002-8156-7492)
- Ashley Frith (ORCID: https://orcid.org/0000-0001-9507-4122)
- Lindsay L. Peterson (ORCID: https://orcid.org/0000-0002-5012-7347)
- Caron Rigden (ORCID: https://orcid.org/0000-0002-9555-1344)
- Foluso O. Ademuyiwa (ORCID: https://orcid.org/0000-0002-6766-2258)
- Katherine N. Weilbaecher (ORCID: https://orcid.org/0000-0002-7137-4742)
- Nusayba Ali Bagegni (ORCID: https://orcid.org/0000-0001-9322-2451)
- Derek Dustin (ORCID: https://orcid.org/0000-0002-3566-0282)
- Liyang Xiong (ORCID: https://orcid.org/0000-0002-3257-7643)
- Katherine Clifton (ORCID: https://orcid.org/0000-0001-8623-995X)
- Sai Chen (ORCID: https://orcid.org/0000-0003-3106-5643)
Institutions
- Washington University in St. Louis (US)
- Guardant (United States) (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-03-20
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3145
- Citations
- 5
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 4.68